JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Systemic Inflammatory Biomarkers as a Predictive Markers for Ovarian Cancer

  • 0Department of Obstetrics and Gynecology, Universitas Padjadjaran, Bandung, Indonesia.
International Journal of Women's Health +

|

May 5, 2025

|

May 5, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Systemic inflammatory biomarkers, like the Systemic Immune Inflammation Index (SII), show promise for diagnosing ovarian malignancy, especially where CA125 tests are unavailable. These markers offer comparable diagnostic value and can serve as accessible complementary tools.

Area Of Science

  • Oncology
  • Inflammation Biology
  • Diagnostic Medicine

Background

  • Ovarian malignancy diagnosis often relies on tumor markers like CA125.
  • CA125 availability can be limited in remote healthcare settings.
  • Alternative diagnostic modalities are needed for accessible ovarian cancer screening.

Purpose Of The Study

  • To investigate the utility of systemic inflammatory biomarkers as complementary diagnostic tools for ovarian malignancy.
  • To evaluate the predictive performance of various inflammatory indices, including MLR, NLR, PLR, SII, and SIRI.
  • To compare the diagnostic accuracy of these biomarkers against histopathological examination.

Main Methods

  • A cross-sectional diagnostic study included 132 patients with adnexal tumors.
  • Complete blood counts were analyzed to calculate Monocyte Lymphocyte Ratio (MLR), Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), Systemic Immune Inflammation Index (SII), and Systemic Inflammatory Response Index (SIRI).
  • Biomarker performance was assessed using AUC and sensitivity, compared to gold-standard histopathology.

Main Results

  • The Systemic Immune Inflammation Index (SII) demonstrated the highest AUC (0.743) and was statistically significant in multivariate analysis (p=0.015).
  • SII exhibited a sensitivity of 71.64% and specificity of 73.84%, with an overall accuracy of 72.72%.
  • Other inflammatory biomarkers (MLR, NLR, PLR, SIRI) also showed significant diagnostic potential.

Conclusions

  • Systemic inflammatory biomarkers, particularly SII, can serve as valuable complementary predictive markers for ovarian malignancy.
  • These accessible biomarkers offer diagnostic values comparable to CA125, especially in resource-limited settings.
  • The findings support the use of inflammatory indices for early detection and improved accessibility of ovarian cancer diagnosis.

Keywords: